Highlights Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
4.97 ^USD	+0.61%		-1.58%	-42.01%

05-15	Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors	CI
05-10	Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK	05-10	CI
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	05-10	MT
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	05-10	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study	01-03	DJ
Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Intensity Therapeutics, Inc. Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023	11-02	CI
Intensity Therapeutics Gets Orphan Drug Label for Three Ingredients in INT230-6	07/09/23	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Intensity Therapeutics Raises $19.5 Million From Public Offering	05/07/23	MT
Intensity Therapeutics Shares Surge in Nasdaq Debut After IPO Pricing	30/06/23	MT
Intensity Therapeutics Prices Upsized IPO at $5 per Share	30/06/23	MT
Intensity Therapeutics, Inc. has completed an IPO in the amount of $19.5 million.	29/06/23	CI
Intensity Therapeutics, Inc. Announces Data from Its Ongoing Phase 1/2 Clinical Trial Demonstrating the Efficacy and Tolerability of Int230-6	03/06/23	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	18/05/23	CI
Intensity Therapeutics, Inc. has completed an IPO in the amount of $8.1 million.	02/02/23	CI
Intensity Therapeutics, Inc. has completed an IPO in the amount of $8.000001 million.	27/01/23	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	13/01/23	CI
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis	18/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Highlights

Filters